You are here: Industry Insights > FLT3

News List

ICR’s ‘resistance-busting’ drug advances into Phase I trial pharmatimes
March 19, 2021
The Institute of Cancer Research, London (ICR) has announced that its ‘resistance-busting’ drug EP0042 has entered a Phase I clinical trial in patients with cancers including acute myeloid leukaemia (AML).
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML drugs
May 20, 2019
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML.
EC grants orphan drug designation for Gilteritinib for the treatment of AML europeanpharmaceuticalreview
April 29, 2019
The European Commission has issued Orphan Designation to gilteritinib for the treatment of patients with acute myeloid leukaemia…
Astellas scores first US blood cancer approval with Xospata pharmaphorum
December 03, 2018
The FDA has approved Astellas’ Xospata for certain patients with acute myeloid leukaemia – the company’s first drug approved in blood cancer.
FDA Approves Gilteritinib americanpharmaceuticalreview
November 30, 2018
On November 28, 2018, the Food and Drug Administration (FDA) approved gilteritinib (XOSPATA, Astellas Pharma) for treatment of adult patients who have relapsed or refractory.......
FDA Approves Xospata drugs
November 29, 2018
FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation.